Bicocca Open Archive

Logo unimib boa
INVERNIZZI, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.780
EU - Europa 6.982
AS - Asia 2.093
SA - Sud America 29
AF - Africa 19
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 12
Totale 25.928
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.596
IT - Italia 1.745
IE - Irlanda 1.257
SE - Svezia 1.225
DE - Germania 1.202
CN - Cina 990
HK - Hong Kong 618
GB - Regno Unito 490
UA - Ucraina 273
AT - Austria 229
CA - Canada 181
VN - Vietnam 154
FI - Finlandia 124
FR - Francia 118
RU - Federazione Russa 97
TR - Turchia 94
IN - India 83
DK - Danimarca 79
NL - Olanda 50
BE - Belgio 31
SG - Singapore 29
BR - Brasile 21
JP - Giappone 21
IR - Iran 16
MY - Malesia 16
PH - Filippine 14
PL - Polonia 12
IL - Israele 11
KR - Corea 11
CH - Svizzera 10
PK - Pakistan 10
AU - Australia 9
RO - Romania 8
A2 - ???statistics.table.value.countryCode.A2??? 7
ES - Italia 7
EU - Europa 6
SC - Seychelles 6
TW - Taiwan 6
GR - Grecia 5
GH - Ghana 4
MM - Myanmar 4
PT - Portogallo 4
SA - Arabia Saudita 4
SK - Slovacchia (Repubblica Slovacca) 4
AL - Albania 3
BD - Bangladesh 3
NZ - Nuova Zelanda 3
AR - Argentina 2
BG - Bulgaria 2
CL - Cile 2
CM - Camerun 2
EC - Ecuador 2
EG - Egitto 2
LK - Sri Lanka 2
MU - Mauritius 2
NO - Norvegia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BZ - Belize 1
DZ - Algeria 1
EE - Estonia 1
HU - Ungheria 1
ID - Indonesia 1
IQ - Iraq 1
JM - Giamaica 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
ME - Montenegro 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
PE - Perù 1
PY - Paraguay 1
Totale 25.928
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.833
Fairfield 1.778
Woodbridge 1.345
Dublin 1.206
Chandler 1.143
Wilmington 1.023
Houston 976
Frankfurt am Main 936
Ashburn 913
Seattle 744
Cambridge 614
Hong Kong 609
New York 555
Dearborn 501
Milan 478
Princeton 468
Jacksonville 371
Lawrence 229
Vienna 224
Altamura 213
Nanjing 198
London 187
San Diego 135
Beijing 127
Shanghai 119
Boardman 101
Chicago 88
Dong Ket 78
Andover 67
Lachine 62
Guangzhou 57
Nanchang 51
Hangzhou 50
Rome 50
Helsinki 49
Toronto 49
Los Angeles 45
Hebei 41
Ottawa 40
Shenyang 38
Falls Church 37
Norwalk 36
Jinan 35
Changsha 33
Fremont 33
Lissone 31
Pune 31
Brussels 29
Jiaxing 28
Tianjin 28
San Mateo 23
Bologna 22
Kunming 22
Monza 22
Washington 22
Mountain View 21
Zhengzhou 20
Leawood 17
Turin 17
Edmonton 16
Kilburn 16
Ningbo 16
Penang 16
Singapore 16
Taizhou 16
Padova 14
Dallas 13
Hefei 13
São Paulo 13
Groningen 12
Mumbai 12
Redmond 12
Garbagnate Milanese 11
Genoa 11
Kiev 11
Kocaeli 11
Lappeenranta 11
Tappahannock 11
Bergamo 10
Como 10
New Bedfont 10
Providence 10
Ferrara 9
Florence 9
Huizen 9
Napoli 9
Perugia 9
Sacramento 9
Bari 8
Bonndorf 8
Carate Brianza 8
Davao City 8
Modena 8
San Jose 8
Vicenza 8
Buffalo 7
Central 7
Changchun 7
Council Bluffs 7
Haikou 7
Totale 20.734
Salva come PNG Salva come JPEG
Nome #
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 399
Validation of the Italian version of fisk fatigue severity score (FFSS) and PBC-40 340
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 323
Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model 322
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 285
A short version of a HRQol questionnaire for Italian and Japanese patients with PBC 240
Knockout of α-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes 230
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 219
Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal-7 microRNA 215
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 206
Better end points needed in primary sclerosing cholangitis trials 204
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 200
Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms 192
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 192
Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload 189
The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective 184
DCLK1, a putative novel stem cell marker in human cholangiocarcinoma 184
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 182
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 182
It's as if PBC didn’t exist: The illness experience of women affected by primary biliary cirrhosis 179
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 178
Dermatological Complications After Solid Organ Transplantation 178
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 176
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 172
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 169
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 169
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 168
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 168
Precision medicine in primary biliary cholangitis 167
Understanding short bowel syndrome: Current status and future perspectives 167
The X-factor in primary biliary cirrhosis: Monosomy X and xenobiotics 166
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 163
Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth 162
Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion 162
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 162
Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells 161
Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma 159
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 159
Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis 157
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma 157
The challenges of primary biliary cholangitis: What is new and what needs to be done 157
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. 156
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 155
High rates of 30-day mortality in patients with cirrhosis and COVID-19 155
Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy 155
Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease 154
AISF position paper on liver disease and pregnancy 154
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 153
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 151
Y chromosome loss in male patients with primary biliary cirrhosis 150
Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth 150
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 150
Validation of the Japanese version of the Fisk Fatigue Severity Score (FFSS) in Japanese patients with primary biliary cirrhosis 149
The Seat of Life. What a Lesson from the Stigmatized Saints 148
Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism 147
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development 147
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 147
MicroRNAs in autoimmunity and inflammatory bowel disease: Crucial regulators in immune response 145
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 143
Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth 142
The Fingerprint of Antimitochondrial Antibodies and the Etiology of Primary Biliary Cholangitis 142
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 142
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 142
“I Miss My Liver.” Nonmedical Sources in the History of Hepatocentrism 141
New Therapeutic Targets in Autoimmune Cholangiopathies 140
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 138
Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma 138
Nicotine Promotes Cholangiocarcinoma Growth in Xenograft Mice 136
Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis 135
miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation 135
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease 134
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 134
Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis 134
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 133
Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation 132
Expert clinical management of autoimmune hepatitis in the real world 131
Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2−/− mice 130
COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy 129
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 129
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study 126
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 126
Immune-mediated drug-induced liver injury: Immunogenetics and experimental models 125
Liver auto-immunology: The paradox of autoimmunity in a tolerogenic organ 124
Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases 124
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls 124
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 124
Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C 124
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease 123
Treatment of PBC-A step forward 123
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 123
Relationship between illness perception, anxiety, depression and fatigue in HCV patients 122
Secretin stimulates biliary cell proliferation by regulating expression of microRNA 125b and MicroRNA let7a in mice 122
Prognostic models in primary biliary cholangitis 122
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 119
Towards common denominators in primary biliary cirrhosis: The role of IL-12 118
Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: A multicentre international study 118
Mapping the human genetic architecture of COVID-19 118
Reply to: “A spotlight on natural killer cells in primary biliary cholangitis” 117
TNF-α polymorphisms in primary biliary cirrhosis: A Northern and Southern Italian experience 116
Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study 115
Totale 16.123
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.079
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.079
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019807 0 0 0 0 0 0 0 0 0 0 394 413
2019/20204.608 441 226 222 399 355 520 566 433 424 597 280 145
2020/20216.102 238 294 750 490 466 640 725 751 472 458 389 429
2021/20223.372 349 274 450 243 204 240 132 212 147 214 312 595
2022/20235.371 601 1.340 437 474 462 807 153 297 443 94 150 113
2023/20244.097 131 159 172 426 549 1.098 753 188 362 248 11 0
Totale 27.576